<i>MET</i> amplification has been described as a putative off-target resistance mechanism, although its clinical relevance remains incompletely understood.<h4>Methods</h4>We conducted a retrospective case series of patients with <i>KRAS G12C</i>-mutant NSCLC treated with sotorasib at the University Hospital Cologne, Germany. Here, KRAS is linked to non-small cell lung carcinoma.